Tamer I. Khayal, Chief Commercial Officer at TransMedics Group, Inc. (TMDX), sold 19,576 shares at $85.18 ($1.6M) on 2024-03-01, disclosed to the SEC on 2024-03-05.
Scheduled sale ($1.6M) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $81.49 | 2,868 | $234K | 14.4% |
| 2 | $81.49 | 2,868 | $234K | 14.4% |
| 3 | $82.28 | 1,842 | $152K | 9.3% |
| 4 | $82.28 | 1,842 | $152K | 9.3% |
| 5 | $83.64 | 3,632 | $304K | 18.7% |
| 6 | $83.64 | 3,632 |
| $304K |
| 18.7% |
| 7 | $84.26 | 424 | $36K | 2.2% |
| 8 | $85.18 | 1,234 | $105K | 6.5% |
| 9 | $85.18 | 1,234 | $105K | 6.5% |
| Total | $82.96 avg | 19,576 | $1.6M | 100% |
| Filing → |
| TMDX | SELL | 2024-12-04 | $187K | — | Filing → |
| TMDX | SELL | 2024-11-13 | $263K | — | Filing → |
| TMDX | SELL | 2024-11-05 | $179K | — | Filing → |